Tamoxifen and fatty fiver disease
10.3760/cma.j.issn.1673-422X.2011.07.016
- VernacularTitle:三苯氧胺与脂肪性肝病
- Author:
Jie SHEN
;
Shengli HE
- Publication Type:Journal Article
- Keywords:
Tamoxifen;
Nonalcoholic fatty liver disease
- From:
Journal of International Oncology
2011;38(7):529-532
- CountryChina
- Language:Chinese
-
Abstract:
Tamoxifen has shown definitive effect when used as the adjuvant hormonal treatment in women with estrogen-receptor-positive breast cancer. However, long-term use of Tamoxifen can induce fatty liver disease. It has been proposed that tamoxifen may act throught mechanisms such as inducing triacylglycerol accumulation in mitochondria, abnormal fatty acid oxidation, and antagonizing actions of estrogen on hepatic lipid metabolism. Therefore, it is necessary to monitor lipid profile and liver function, conduct regular ultrasonography and CT examination in patients receiving tamoxifen treatment. Replacing tamoxifen with toremifene oraromatase inhibitors, or using lipid-lowering medicines may help prevent tamoxifen-induced fatty liver disease.
